North Carolina’s Research Triangle Park (RTP) has been recognized as the fourth most prominent biotech hub in the United States, following industry giants such as Boston, San Francisco, and San Diego. This prestigious ranking, as reported by the authoritative source Fierce Biotech, reflects RTP’s significant impact on the biotech and pharmaceutical sectors.

The assessment, conducted by CBRE Research, highlights the surge in demand for laboratory space and the expansion of lab facilities within the region. RTP’s rise to prominence is not due to sheer size or fame but rather its strategic position as a nexus of research and development nestled between Raleigh and Durham.

Innovative pharmaceuticals are at the forefront of RTP’s offerings. Notably, Novartis has recently received approval to commence production of Zolgensma, a groundbreaking gene therapy for spinal muscular atrophy, at their expansive 170,000-square-foot facility.

Adjacent to RTP, Morrisville is also making waves with new manufacturing sites for Enzyvant and Kriya Therapeutics, both pioneering companies in regenerative and gene therapy, respectively.